ROVI announces an agreement with Biogaran for the marketing of its enoxaparin biosimilar in France


No votes yet
 
Related
In compliance with the disclosure obligations set forth in Article 227 of Law 6/2023, of 17 March, on Securities Markets and Investment...
1 min
18/11/2025
​Operating revenue in the first nine months of 2025 was 525.1 million euros, a 7% decrease on the first nine months of 2024, mainly due...
4 min
06/11/2025
  Madrid, Spain –21 October 2025. Today, Laboratorios Farmacéuticos Rovi, S.A. (hereinafter, “ROVI”), a pan-European pharmaceutical...
3 min
21/10/2025